Overview

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the safety and pharmacokinetics (the rate at which the body eliminates the trial drug) of NNC 0128-0000-2011 compared to NNC 0128-0000-2021 when given for the first time to healthy human subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S